## Berthe M P Aleman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8285399/publications.pdf

Version: 2024-02-01

27 papers 3,423 citations

16 h-index 27 g-index

27 all docs

27 docs citations

times ranked

27

3680 citing authors

#	Article	IF	CITATIONS
1	Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin's Disease. Journal of Clinical Oncology, 2003, 21, 3431-3439.	0.8	663
2	Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood, 2007, 109, 1878-1886.	0.6	635
3	Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 373, 2499-2511.	13.9	474
4	Long-Term Risk of Second Malignancy in Survivors of Hodgkin's Disease Treated During Adolescence or Young Adulthood. Journal of Clinical Oncology, 2000, 18, 487-487.	0.8	416
5	Cardiovascular Disease After Hodgkin Lymphoma Treatment. JAMA Internal Medicine, 2015, 175, 1007.	2.6	373
6	Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1081-1091.	0.4	178
7	Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematology,the, 2015, 2, e492-e502.	2.2	123
8	Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast CancerÂSurvivors. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1061-1072.	0.4	88
9	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood, 2019, 133, 237-245.	0.6	85
10	Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. International Journal of Radiation Oncology Biology Physics, 2019, 103, 595-604.	0.4	80
11	Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood, 2009, 113, 3679-3681.	0.6	72
12	Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. British Journal of Cancer, 2018, 119, 408-418.	2.9	50
13	Cardiovascular Morbidity and Mortality After Treatment for Ductal Carcinoma In Situ of the Breast. Journal of the National Cancer Institute, 2014, 106, .	3.0	30
14	Heart failure after treatment for breast cancer. European Journal of Heart Failure, 2020, 22, 366-374.	2.9	28
15	Myocardial dysfunction in longâ€ŧerm breast cancer survivors treated at ages 40–50 years. European Journal of Heart Failure, 2020, 22, 338-346.	2.9	25
16	High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Cancer, 2019, 125, 990-999.	2.0	23
17	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. Breast Cancer Research and Treatment, 2021, 185, 205-214.	1.1	19
18	Risk of diabetes after para-aortic radiation for testicular cancer. British Journal of Cancer, 2018, 119, 901-907.	2.9	14

#	Article	IF	CITATIONS
19	A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging. Practical Radiation Oncology, 2019, 9, e506-e515.	1.1	9
20	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. BMC Cancer, 2017, 17, 112.	1.1	8
21	Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma. British Journal of Haematology, 2019, 186, e103-e108.	1.2	6
22	Prognosis of acute coronary syndromes after radiotherapy for breast cancer. Radiotherapy and Oncology, 2020, 146, 110-117.	0.3	6
23	Comparing causes of death of Hodgkin lymphoma and breast cancer patients between medical records and cause-of-death statistics. Clinical Epidemiology, 2018, Volume 10, 1523-1531.	1.5	5
24	Overall and diseaseâ€specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer. Cancer Medicine, 2019, 8, 190-199.	1.3	5
25	Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. Journal of Clinical Medicine, 2020, 9, 190.	1.0	5
26	Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases. PLoS ONE, 2020, 15, e0243178.	1.1	2
27	Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors. Digestive Endoscopy, 2022, 34, 163-170.	1.3	1